Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-03-07 10:01 am Purchase | 2025-02-28 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 7,851,098 10.300% | 983,414 (+14.32%) | Filing History |
| 2024-11-12 10:40 am Purchase | 2024-11-08 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 6,867,684 9.064% | 1,211,762 (+21.42%) | Filing History |
| 2024-02-14 09:12 am Purchase | 2023-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | Avoro Capital Advisors LLC | 5,666,666 7.700% | 766,666 (+15.65%) | Filing History |
| 2024-02-14 07:43 am Sale | 2023-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | DRIEHAUS CAPITAL MANAGEMENT LLC | 4,345,180 5.880% | -336,617 (-7.19%) | Filing History |
| 2024-02-09 10:05 am Purchase | 2024-02-08 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 5,655,922 7.556% | 965,093 (+20.57%) | Filing History |
| 2024-02-08 10:03 am Purchase | 2023-12-29 | 13G | Xenon Pharmaceuticals Inc. XENE | WELLINGTON MANAGEMENT CO LLP | 4,162,654 5.560% | 4,162,654 (New Position) | Filing History |
| 2023-02-14 4:19 pm Sale | 2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | Point72 Asset Management L.P. | 1,178,501 1.900% | -1,828,637 (-60.81%) | Filing History |
| 2023-02-14 09:41 am Sale | 2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | Avoro Capital Advisors LLC | 4,900,000 7.800% | -85,000 (-1.71%) | Filing History |
| 2023-02-13 8:20 pm Sale | 2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | BIOTECHNOLOGY VALUE FUND L P | 1,271,243 2.000% | -3,034,297 (-70.47%) | Filing History |
| 2023-02-10 12:10 pm Purchase | 2022-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | DRIEHAUS CAPITAL MANAGEMENT LLC | 4,681,797 7.490% | 1,558,568 (+49.90%) | Filing History |
| 2023-02-09 12:46 pm Purchase | 2023-02-09 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 4,690,829 7.500% | 780,812 (+19.97%) | Filing History |
| 2022-03-18 7:18 pm Sale | 2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | BIOTECHNOLOGY VALUE FUND L P | 4,305,540 8.200% | -851,946 (-16.52%) | Filing History |
| 2022-02-14 4:37 pm Purchase | 2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | Point72 Asset Management L.P. | 3,007,138 5.800% | 365,885 (+13.85%) | Filing History |
| 2022-02-14 1:53 pm Purchase | 2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | BIOTECHNOLOGY VALUE FUND L P | 5,157,486 9.990% | 1,658,140 (+47.38%) | Filing History |
| 2022-02-14 09:14 am Purchase | 2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | DRIEHAUS CAPITAL MANAGEMENT LLC | 3,123,229 6.050% | 3,123,229 (New Position) | Filing History |
| 2022-02-11 5:09 pm Sale | 2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | ORBIMED ADVISORS LLC | 631,000 1.220% | -1,080,305 (-63.13%) | Filing History |
| 2022-02-11 10:00 am Purchase | 2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | Avoro Capital Advisors LLC | 4,985,000 9.700% | 2,185,000 (+78.04%) | Filing History |
| 2022-02-10 11:23 am Sale | 2021-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE | ADAGE CAPITAL PARTNERS GP LLC | 665,000 1.290% | -1,785,000 (-72.86%) | Filing History |
| 2022-02-09 10:04 am Purchase | 2022-02-08 | 13G | Xenon Pharmaceuticals Inc. XENE | FMR LLC | 3,910,017 7.579% | 1,284,465 (+48.92%) | Filing History |
| 2021-10-28 5:24 pm Purchase | 2021-10-27 | 13G | Xenon Pharmaceuticals Inc. XENE | Point72 Asset Management L.P. | 2,641,253 5.100% | 2,641,253 (New Position) | Filing History |